Compare Stocks → Massive $1 Trillion AI Superproject Underway Worldwide (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMSNASDAQ:APTXNASDAQ:ETONOTCMKTS:HBPCF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsETONEton Pharmaceuticals$3.66+1.9%$3.56$2.42▼$5.81$94.03M1.1965,368 shs62,267 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$31.59M-0.04N/AN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%APTXAptinyx0.00%0.00%0.00%0.00%+69.31%ETONEton Pharmaceuticals-1.37%-1.10%+12.54%-19.33%-2.71%HBPCFHelix BioPharma0.00%0.00%0.00%-5.03%-5.03%Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals2.5781 of 5 stars3.55.00.00.00.60.81.3HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas PharmaceuticalsN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AETONEton Pharmaceuticals3.00Buy$9.00145.90% UpsideHBPCFHelix BioPharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest HBPCF, ADMS, ETON, and APTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2024ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 5/22/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49APTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AETONEton Pharmaceuticals$31.64M2.97$0.00 per share1,138.99$0.60 per share6.10HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AETONEton Pharmaceuticals-$940K$0.0491.50∞N/A2.66%5.65%2.92%8/8/2024 (Estimated)HBPCFHelix BioPharma-$4.69M-$0.03N/A∞N/AN/A-2,505.18%-377.54%6/12/2024 (Estimated)Latest HBPCF, ADMS, ETON, and APTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024ETONEton Pharmaceuticals-$0.02-$0.03-$0.01-$0.03$8.30 million$7.97 million 3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AAPTXAptinyxN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17APTXAptinyxN/AN/AN/AETONEton PharmaceuticalsN/A1.591.43HBPCFHelix BioPharmaN/A1.461.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%APTXAptinyxN/AETONEton Pharmaceuticals27.86%HBPCFHelix BioPharmaN/AInsider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%APTXAptinyx10.97%ETONEton Pharmaceuticals14.89%HBPCFHelix BioPharma7.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableAPTXAptinyx12N/AN/ANot OptionableETONEton Pharmaceuticals3025.69 million21.87 millionOptionableHBPCFHelix BioPharma9229.44 million212.00 millionNot OptionableHBPCF, ADMS, ETON, and APTX HeadlinesRecent News About These CompaniesApril 17, 2024 | cnet.comHelix Dusk Luxe Mattress Review 2024: A Comfortable Pillow-Top BedJanuary 22, 2024 | finance.yahoo.comHelix BioPharma Corp. Reports Voting ResultsDecember 14, 2023 | finance.yahoo.comHelix BioPharma Corp. Announces Fiscal 2024 First Quarter ResultsNovember 28, 2023 | morningstar.comHelix BioPharma Corp HBPOctober 27, 2023 | msn.comHelix Biopharma GAAP EPS of -C$0.03October 27, 2023 | finance.yahoo.comHelix BioPharma Corp. Announces Fiscal 2023 Year-End ResultsSeptember 14, 2023 | uk.investing.comHelix BioPharma Corp. (HBP)June 29, 2023 | finance.yahoo.comHELIX BIOPHARMA CORP (HBPCF) stock forecast and price targetMay 24, 2023 | etonline.com15 Best Memorial Day Mattress Sales You Can Shop Right Now: Nectar, Helix, Tempur-Pedic and MoreMay 14, 2023 | thestreet.comHelix Energy Up on BP Spill ContractMarch 15, 2023 | finance.yahoo.comHelix Biopharma Corp. Announces Fiscal 2023 Second Quarter ResultsFebruary 2, 2023 | genengnews.comReflections on the Double Helix’s Platinum AnniversaryJanuary 31, 2023 | finance.yahoo.comIs Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?September 3, 2022 | seekingalpha.comHelix BioPharma appoints R&D headSeptember 2, 2022 | benzinga.comProactive news headlines including Shell, Maverix Metals, Helix BioPharma, Wellteq Digital Health and Trees CorpMay 18, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Appointment of New Chief Financial OfficerApril 18, 2022 | ca.proactiveinvestors.comHelix BioPharma appoints Artur Gabor as its new CEO; adds three new board membersApril 13, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement SubscriptionApril 13, 2022 | finance.yahoo.comHelix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement SubscriptionMarch 18, 2022 | seekingalpha.comHelix Biopharma GAAP EPS of -$0.01New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamas PharmaceuticalsNASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.AptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
